RT期刊文章SR电子T1不同年龄组发病率NIA-LOAD / NCRAD痴呆和阿尔茨海默病的神经学和EFIGA家庭(P2.148)摩根富林明乔神经病学FD Lippincott Williams &威尔金斯SP P2.148 VO 82是10补充A1巴蒂尼Vardarajan A1凯利Faber A首页1托马斯鸟A1大卫·班尼特A1罗杰·罗森博格A1布拉德利Boeve A1尼尔Graff-Radford A1艾莉森Goate A1马丁大学法洛A1罗伯特甜A1 Rafeal Lantigua A1马丁Medrano A1露丝Ottman A1丹尼尔Schaid A1 Tatiana Foroud A1理查德马斯年2014 UL //www.ez-admanager.com/content/82/10_Supplement/P2.148.abstract AB目的:评估不同年龄组发病率痴呆和阿尔茨海默病(AD)的大型多元化家庭背景:广告大家庭的发生率假设是高于一般人群。我们估计不同年龄组痴呆的发病率在家庭招募和负载的一部分NIA-LOAD / NCRAD研究和加勒比拉美裔EFIGA研究。我们也估计的血缘关系水平加勒比拉美裔人口占外加剂。设计/方法:限制分析家庭随访和完整的表型信息,396 NIA-LOAD / NCRAD和242年加勒比裔家庭进行了研究。风险在943家庭成员在NIA-LOAD / NCRAD家庭,126年(13.4%)转换成痴呆,其中有109(86.5%)达到标准负载。683名高危家庭成员在加勒比海拉美裔家庭,174发达痴呆(25.3%),其中145(83.3%)负载。我们估计的血缘关系在加勒比海拉美裔人占人口的掺合料,使用获得软件中实现的算法。结果:一年一度的痴呆的发病率和负载NIA-LOAD / NCRAD家庭分别为2.9%和2.7%(65 - 74年),6.5%和5.6%(75 - 84年),分别为7.9%和7.1%(85以上)。加勒比裔家庭中发病率稍高5.9%和4.6%(65 - 74年),10.3%和7.5%(75 - 84年)和10.1%和7.2%(85年以上)。对比结果和以人群为基础的估计,发病率增加了三倍NIA-LOAD / NCRAD家庭(标准化发病率比= 3.44),高出两倍的加勒比裔家庭相比NIA-LOAD / NCRAD家庭先生(= 1.70)。 The level of inbreeding in the Caribbean Hispanic subjects ranges from 0.018 (±0.04) to 0.002 (±0.018) which indicates excess sharing between unrelated subjects. CONCLUSIONS:: As hypothesized, the incidence rates for familial dementia and LOAD were significantly higher in than population based estimates. The higher incidence of disease could be due to enrichment of AD related variants due to high consanguinity in the Caribbean Hispanics Study Supported by:Disclosure: Dr. Vardarajan has nothing to disclose. Dr. Faber has nothing to disclose. Dr Bird has received licensing fee payments from Athena Diagnostics Inc. Dr. Bennett has received personal compensation for activities with Danone Inc., Dr. Wilmar Schwabe GmbH & Co., KG Pharmaceuticals, and Eli Lilly & Company. Dr. Bennett has received research support from Danone, Inc. Dr. Rosenberg has received personal compensation for activities with Janssen Pharmaceutica, and Novartis. Dr. Rosenberg has received personal compensation in an editorial capacity for the Journal of the American Medical Association, and the Journal of Neurological Sciences. Dr. Rosenberg has received license fee payments from Vitruvian Inc. Dr. Rosenberg has received research support from Janssen Pharmaceutica and Novartis. Dr. Boeve has received research support from Cephalon, Inc., Allon Therapeutics, and GE Healthcare. Dr. Graff-Radford has received personal compensation for activities with Codman as a member of a scientific advisory board. Dr. Graff-Radford has received personal compensation in an editorial capacity for The Neurologist. Dr. Graff-Radford has received research support from Janssen, Pfizer Inc., Medivation, Forest Laboratories Inc., and Allon. Dr. Goate has nothing to disclose. Dr. Farlow has received personal compensation for activities with Accera, Alltech, Avanir Pharmaceuticals, Eisai Inc., Helicon, Medavante, Medivation Inc., Merck & Co. Inc., Novartis, Pfizer Inc., Prana Biotech, Roche Diagnostics Corp., Sanofi-Aventis Pharmaceuticals Inc., Schering-Plough Corp., and Eli Lilly & Co. Dr. Farlow has received research support from Eli Lilly & Co., Novartis, Sanofi Aventis Pharmaceuticals, Inc., Roche Diagnostics Corporation, and Eisai Inc. Dr. Sweet has nothing to disclose. Dr. Lantigua has nothing to disclose. Dr. Medrano has nothing to disclose. Dr. Ottman has nothing to disclose. Dr. Schaid has nothing to disclose. Dr. Foroud has nothing to disclose. Dr. Mayeux has nothing to disclose.Tuesday, April 29 2014, 7:30 am-11:00 am